Therapeutics for people with COVID-19 [ID4038]
In development [GID-TA10936] Expected publication date: TBC
Search results
573 results
-
-
Alpelisib in combination with fulvestrant for treating advanced hormone-receptor positive, HER2-negative, PIK3CA-mutated breast cancer [ID3929]
In development [GID-TA10825] Expected publication date: 29 July 2022
-
Nintedanib for treating idiopathic pulmonary fibrosis in people with a forced vital capacity above 80% predicted (part-review of technology appraisal guidance 379) [ID4062]
In development [GID-TA10975] Expected publication date: 01 March 2023
-
Nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma [ID1609]
In development [GID-TA10498] Expected publication date: TBC
-
Pembrolizumab plus chemotherapy for untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer [ID1546]
In development [GID-TA10417] Expected publication date: 29 June 2022
-
Cabozantinib for previously treated advanced hepatocellular carcinoma [ID3917]
In development [GID-TA10805] Expected publication date: 12 October 2022
-
Romosozumab for treating severe osteoporosis [ID3936]
In development [GID-TA10828] Expected publication date: TBC
-
Mavacamten for treating symptomatic obstructive hypertrophic cardiomyopathy [ID3928]
In development [GID-TA10824] Expected publication date: 01 March 2023
-
Melphalan for haematological diseases before allogeneic haematopoietic stem cell transplant [ID3969]
In development [GID-TA10852] Expected publication date: TBC
-
Diroximel fumarate for treating relapsing-remitting multiple sclerosis [ID1673]
In development [GID-TA10714] Expected publication date: 18 May 2022
-
Vadadustat for treating anaemia in people with chronic kidney disease [ID3821]
In development [GID-TA10877] Expected publication date: TBC
-
Rimegepant for treating or preventing migraine [ID1539]
In development [GID-TA10839] Expected publication date: 01 March 2023
-
Tepotinib for treating advanced non-small-cell lung cancer with MET gene alterations [ID3761]
In development [GID-TA10630] Expected publication date: 18 May 2022
-
Icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in people with raised triglycerides [ID3831]
In development [GID-TA10736] Expected publication date: 20 July 2022
-
Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors [ID3813]
In development [GID-TA10691] Expected publication date: 13 July 2022
-
Efgartigimod for treating generalised myasthenia gravis [ID4003]
In development [GID-TA10986] Expected publication date: TBC
-
Ravulizumab for treating refractory antibody positive generalised myasthenia gravis [ID4019]
In development [GID-TA10987] Expected publication date: TBC
-
Voxelotor for treating sickle cell disease [ID1403]
In development [GID-TA10505] Expected publication date: 01 March 2023
-
Levodopa, carbidopa monohydrate and entacapone intestinal gel for treating the symptoms of advanced Parkinson's disease [ID4005]
In development [GID-TA10983] Expected publication date: TBC
-
Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (CDF review of TA505) [ID1635]
In development [GID-TA10781] Expected publication date: TBC
-
Burosumab for treating FGF23-related hypophosphataemia in tumour-induced osteomalacia [ID3924 ]
In development [GID-TA10822] Expected publication date: TBC
-
Venetoclax for treating chronic lymphocytic leukaemia (CDF review of TA487) [ID3886]
In development [GID-TA10890] Expected publication date: 15 June 2022
-
Zanubrutinib for treating Waldenström's macroglobulinaemia [ID1427]
In development [GID-TA10705] Expected publication date: 17 August 2022
-
Ibrutinib for treating Waldenstrom's macroglobulinaemia (CDF Review of TA491) [ID3778]
In development [GID-TA10827] Expected publication date: 08 June 2022
-
Faricimab for treating wet age-related macular degeneration [ID3898 ]
In development [GID-TA10799] Expected publication date: TBC
-
Faricimab for treating diabetic macular oedema [ID3899]
In development [GID-TA10798] Expected publication date: TBC
-
Risankizumab for previously treated active psoriatic arthritis [ID1399]
In development [GID-TA10819] Expected publication date: 19 October 2022
-
Imlifidase for preventing kidney transplant rejection in people with chronic kidney disease [ID1672]
In development [GID-TA10552] Expected publication date: 13 July 2022
-
Avacopan for treating severe active granulomatosis with polyangiitis or microscopic polyangiitis [ID1581]
In development [GID-TA10740] Expected publication date: 13 July 2022
-
Tebentafusp for treating advanced (unresectable or metastatic) uveal melanoma [ID1441]
In development [GID-TA10428] Expected publication date: 20 July 2022
-
Abemaciclib for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer [ID3857]
In development [GID-TA10749] Expected publication date: TBC
-
Sacituzumab govitecan for treating unresectable locally advanced or metastatic triple-negative breast cancer after 2 or more therapies [ID3942]
In development [GID-TA10829] Expected publication date: 17 August 2022
-
Olaparib for adjuvant treatment of high-risk HER2-negative, BRCA-positive early breast cancer after chemotherapy [ID3893]
In development [GID-TA10903] Expected publication date: 03 January 2023
-
Pegunigalsidase alfa for treating Fabry disease [ID3904]
In development [GID-TA10790] Expected publication date: TBC
-
Upadacitinib for treating moderately to severely active ulcerative colitis [ID3953]
In development [GID-TA10866] Expected publication date: 04 January 2023
-
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after trastuzumab and a taxane [ID3909]
In development [GID-TA10804] Expected publication date: 04 January 2023
-
Upadacitinib, abrocitinib and tralokinumab for dermatitis [ID3960]
In development [GID-TA10856] Expected publication date: 17 October 2022
-
Cabozantinib for previously treated metastatic differentiated thyroid cancer in people 12 years and over when radioactive iodine has failed or is not suitable [ID4046]
In development [GID-TA10932] Expected publication date: TBC
-
Pembrolizumab for adjuvant treatment of renal cell carcinoma [ID3810]
In development [GID-TA10693] Expected publication date: 20 July 2022
-
Ritlecitinib for treating moderate to severe alopecia areata in people 12 years and over [ID4007]
In development [GID-TA11037] Expected publication date: TBC
-
Selpercatinib for untreated RET fusion-positive advanced non-small-cell lung cancer [ID4056]
In development [GID-TA11012] Expected publication date: TBC
-
Tisagenlecleucel for treating follicular lymphoma after 2 or more therapies [ID3950]
In development [GID-TA10849] Expected publication date: 19 July 2023
-
Eflornithine for maintenance treatment of high-risk neuroblastoma after 1 therapy in people up to 21 years [ID4060]
In development [GID-TA10990] Expected publication date: TBC
-
Relugolix–estradiol–norethisterone acetate for treating moderate to severe symptoms of uterine fibroids [ID3842]
In development [GID-TA10734] Expected publication date: 22 June 2022
-
Durvalumab for maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiation (CDF review of TA578) [ID3885]
In development [GID-TA10894] Expected publication date: 27 June 2022
-
Pembrolizumab with lenvatinib for previously treated advanced, metastatic or recurrent endometrial cancer [ID3811]
In development [GID-TA10692] Expected publication date: 04 January 2023
-
Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer (Review of TA619) [ID3779]
In development [GID-TA10901] Expected publication date: 23 November 2022
-
Lu vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more therapies [ID3840]
In development [GID-TA10730] Expected publication date: 23 November 2022
-
Pembrolizumab in combination with chemotherapy for neoadjuvant treatment of triple negative breast cancer [ID1500]
In development [GID-TA10399] Expected publication date: 23 November 2022
-
Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer [ID3920 ]
In development [GID-TA10802] Expected publication date: TBC